Navigation Links
Novel screening tests for liver cancer
Date:4/25/2013

ted: "These findings will be welcomed by physicians as they validate urinary metabolic profiling as a potential screening tool for HCC, with superior diagnostic accuracy to serum AFP and if investigated further and put into practice this non-invasive technique could simplify and improve clinical diagnosis and outcomes for patients."

Similarly, detection of CC remains a diagnostic challenge and physicians will be encouraged by results from a Phase II study showing that a combined bile and urine proteomic test increased diagnostic accuracy of CC in patients with biliary strictures (an abnormal narrowing of the common bile duct) of unknown origin.

Having recently established diagnostic peptide marker models in bile and urine to detect both local and systemic changes during CC progression, investigators combined both models with the aim of reaching a higher diagnostic accuracy.

The data demonstrated this model enables impressive CC-diagnosis with an accuracy of more than 90% that is most applicable for patients with biliary strictures of unknown origin referred to endoscopy.

Prof. Mark Thursz added: "These important findings substantially improve the diagnosis of CC and may lead to early therapy and improved prognosis. Overall both data sets demonstrate the increasing value of proteomic and metabonomic techniques and if confirmed by further investigation, clinicians may soon be using simple urine dip-stick tests to diagnose HCC and CC."

A logistic regression model composed of the bile and urine proteomic classification factors lead to an area under curve (AUC) of 0.96, and 92% sensitivity and 84% specificity at the best cut-off. Only three of the 36 CC patients were false negative and two of the 33 PSC patients were false positive classified. Inclusion of CA19-9 and bilirubin values to the logistic regression model was of minor benefit.

Cholangiocarcinoma or bile duct cancer is rare and almost always adenocarcinom
'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-790-013-8904
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... articles in the Society of Interventional Radiology,s flagship publication, ... report on studies related to peripheral arterial disease or ... Month. In one study, researchers determined that Framingham Risk ... cardiovascular risk) alone may not be enough to definitively ...
... new physics-based theory could give researchers a deeper understanding ... large polymers. This advance provides a better picture of ... for plastics and other polymeric materials. Kenneth S. ... materials science and engineering at the University of Illinois, ...
... landmark Cleveland institutions have come together to launch a ... sclerosis (MS). Researchers at the Cleveland Clinic, University Hospitals ... on a ground-breaking study that will test the feasibility ... to treat MS. In patients with MS, the ...
Cached Biology News:Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 3Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 4Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 5New theory may shed light on dynamics of large-polymer liquids 2Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 2Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 3Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 4Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 5
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:8/3/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), ... of autologous cell therapies, announced today that RepliCel,s CEO, ... held in Minneapolis, Minnesota on August ... will highlight RepliCel,s 18-month milestones including CE Mark for its ... , clinical data from both RCT-01 (tendon) and RCS-01 (skin) ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... market analysis and premium industry insights on the global resorcinol industry. The report ... collective study of vivid market scenarios and analysis of primary and secondary inputs ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... Scientists from the University of Pennsylvania have developed ... years and retrieving that data a thousand times ... Flash memory and micro-drives, all using less power ... an assistant professor in the Department of Materials ...
... Sept. 17 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... developing, manufacturing and marketing biopharmaceutical,products, will present at ... on Tuesday, September 25, 2007 at 10:30 AM ... and can be accessed on the Events,section of ...
... Bermuda, Sept. 17 Warner Chilcott,Limited (Nasdaq: WCRX ... a non-final Action Closing Prosecution from the U.S. Patent ... ordered a,reexamination of LEO,s US Patent No. 6,753,013 (the ... R&D. The 013 Patent covers TACLONEX,and certain of LEO,s ...
Cached Biology Technology:Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3
... The NEW HandyStep electronic from ... repeat pipetting. It is the only ... most standard syringe tips, including BRAND ... Combi-Tips Plus, Fisherbrand Dispenser Tips,and VWRbrand ...
... can be used for efficient, mild and ... for ELISA or other assays for protein ... are bound with high efficiency to the ... will not elute during the assay due ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
Biology Products: